Risperidone and liver function tests in children and adolescents: A short-term prospective study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 3, 2008, Pages 849-857

  Erdogan, Ayten ^a   Atasoy, Nuray ^a   Akkurt, Hanife ^b   Ozturk, Devrim ^a   Karaahmet, Elif ^a   Yalug, Irem ^c   Yalug, Kivanc ^d   Ankarali, Handan ^a   Balcioglu, Ibrahim ^e  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^b Erzurum Numune Hastanesi   (Turkey)

^c KOCAELI UNIVERSITY   (Turkey)

^d MARMARA UNIVERSITY   (Turkey)

^e ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Atypical antipsychotic; Hepatotoxicity; Liver enzymes; Risperidone; Side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; METHYLPHENIDATE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CONTROLLED STUDY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; JAUNDICE; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; SEDATION; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTIPSYCHOTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 39749186682     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.12.032     Document Type: Article

References (60)

1. Aman M.G., Arnold L.E., McDougle C.J., Vitiello B., Scahill L., Davies M., et al. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15 6 (2005) 869-884
2. Armenteros J.L., Whitaker A.H., Welikson M., Stedge D.J., and Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 36 (1997) 694-700
3. Atasoy, N., Erdogan, A., Yalug, I., Ozturk, U., Konuk, N., Atik, L., et al. (2007). A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry; 15; 31(6): 1255-60.
4. Buitelaar J.K., van der Gaag R.J., Cohen-Kettenis P., and Melman C.T. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62 4 (2001) 239-248
5. Cepelak I., Lipovac K., Juretic D., and Birek Z. Effects of neuroleptic phenothiazines on the activities of aminotransferases and gammaglutamyltransferase in serum and liver. J Clin Chem Clin Biochem 24 (1986) 583-587
6. Chitturi S., and George J. Hepatotoxicity of commonly used drugs: nonsteroidal antiinflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipidlowering agents, psychotropic drugs. Semin Liver Dis 22 2 (2002) 169-183
7. Cordeiro Jr. Q., and Elkis H. Pancreatitis and cholestatic hepatitis induced by risperidone. J Clin Psychopharmacol 21 5 (2001) 529-530
8. Dincsoy H.P., and Saelinger D.A. Haloperidol-induced chronic cholestatic liver disease. Gastroenterology 83 (1982) 694-700
9. Dölle W., and Martini G.A. In: Rahn K.H. (Ed). Erkrankungen durch Arzneimittel (1984), Thieme-Verlag, Berlin 371-409
10. Dumotier G., Cabaret W., Stamatiais L., Saba G., Benadriha R., Rocamora J.F., et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 28 6 (2002) 542-551
11. Erdogan A., Kocabasoglu N., Yalug I., Ozbay G., and Senturk H. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med 34 1 (2004) 83-89
12. Findling R.L., McNamara N.K., Branicky L.A., Schluchter M.D., Lemon E., and Blumer J.L. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39 (2000) 509-516
13. Findling R.L., Aman M.G., Eerdekens M., Derivan A., and Lyons B. Risperidone disruptive behavior study group. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161 4 (2004) 677-684
14. Fleischhaker C., Heiser P., Hennighausen K., Herpertz-Dahlmann B., Holtkamp K., Mehler-Wex C., et al. Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 114 (2007) 273-280
15. Frazier J.A., Biederman J., Tohen M., Feldman P.D., Jacobs T.G., Toma V., et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11 (2001) 239-250
16. Fuller M.A., Simon M.R., and Reedman L. Risperidone-associated hepatotoxicity. J Clin Psychopharmacol 16 1 (1996) 84-85
17. Gaffney G.r., Perry P.j., Lund B.c., Bever-Sti{dotless}lle K.a., Arndt S., and Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's Syndrome. J Am Acad Child Adolesc Psychiatry 41 3 (2002) 330-336
18. Gaertner I., Altendorf K., Batra A., and Gaertner H.J. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol 21 2 (2001) 215-222
19. Garcia-Unzueta M.T., Herran A., Sierra-Biddle D., Amado J.A., Vazquez-Barquero J.L., and Alvarez C. Alterations of liver function test in patients treated with antipsychotics. J Clin Lab Anal 17 6 (2003) 216-218
20. Gonzalez-Heydrich J., Raches D., Wilens T.E., Leichtner A., and Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry 42 10 (2003) 1227-1233
21. Holtmann M., Kopf D., Mayer M., Bechtinger E., and Schmidt M.H. Risperidone-associated steatohepatitis and excessive weight-gain. Pharmacopsychiatry 36 5 (2003) 206-207
22. Hummer M., Kurz M., Kurtzhaler I., Oberbauer H., Miller C., and Fleischhacker W.W. Hepatotoxicity of Clozapine. J Clin Pharmacol 17 (1997) 314-317
23. Hütteroth T.H. Medikamenteninduzierte und toxische Leberschäden. In: Meyer K.H. (Ed). Hepatologie in Klinik und Praxis (1989), Thieme-Verlag, Berlin 404-411
24. Kafali G., Erselcan T., and Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr 38 2 (1999) 93-98 (Phila)
25. Kaplan S.L., Simms R.M., and Busner J. Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 33 (1994) 35-44
26. Kelly D.L., Conley R.R., Love R.C., Horn D.S., and Ushchak C.M. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8 (1998) 151-159
27. Krebs S., Dormann H., Muth-Selbach U., Hahn E.G., Brune K., and Schneider H.T. Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 13 1 (2001) 67-69
28. Kumra S., Herion D., Jacobsen L.K., Briguglia C., and Grothe D. Case study: risperidoneinduced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 36 5 (1997) 701-705
29. Landau J., and Martin A. J Am Acad Child Adolesc Psychiatry 37 10 (1998) 1007-1008
30. Lewis J.H. Drug-induced liver disease. Med Clin North Am 84 5 (2000) 1275-1311
31. Llinares Tello F., Hernandez Prats C., Bosacoma Ros N., Perez Martinez E., Climent Grana E., Navarro Polo J.N., et al. Acute cholestatic hepatitis probably associated with risperidone. Int J Psychiatry Med 35 2 (2005) 199-205
32. Malone R.P., Mai{dotless}sli{dotless}n G., Choudhury M.S., Gi{dotless}fford C., and Delaney M.A. Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41 2 (2002) 140-147
33. Martin A., Landau J., Leebens P., Ulizio K., Cicchetti D., Scahill L., et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 10 (2000) 259-268
34. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347 (2002) 314-321
35. Moran J.R., Ghishan F.K., Halter S.A., and Greene H.L. Steatohepatitis in obese children: a cause of chronic liver dysfunction. Am J Gastroenterol 78 6 (1983) 374-377
36. Mouradian-Stamatiadis L., Dumortier G., Januel D., Delmas B.A., and Cabaret W. Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients. Prog Neuro-Psychopharmacol Biol Psychiatry 26 7-8 (2002) 1409-1411
37. Nicolson R., Awad G., and Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37 (1998) 372-376
38. Obata T. Intrahepatic cholestasis and hyperbilirubinemia in ethynyl estradiol and chlorpromazine-treated rats. Gastroenterol Jpn 18 (1983) 538-548
39. Ozcanli T., Erdogan A., Ozdemir S., Onen B., Ozmen M., Doksat K., et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuro-Psychopharmacol Biol Psychiatry 30 6 (2006) 1163-1166
40. Pae C.U., Lim H.K., Kim T.S., Kim J.J., Lee C.U., Lee S.J., et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol 20 3 (2005) 173-176
41. Pappadopulos E., Macintyre Ii J.C., Crismon M.L., Findling R.L., Malone R.P., Derivan A., et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. J Am Acad Child Adolesc Psychiatry 42 2 (2003) 145-161
42. Perry R., Pataki C., Munoz-Silva D.M., Armenteros J., and Silva R.R. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 7 3 (1997) 167-179
43. Radzik J., Grotthus B., and Leszek J. Disorder of liver functions in a schizophrenic patient after long-term risperidone treatment-case report. Psychiatr Pol 39 2 (2005) 309-313
44. Ratzoni G., Gothelf D., Brand-Gothelf A., Reidman J., Kikinzon L., Gal G., et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41 (2002) 337-343
45. Safer D.J. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24 4 (2004) 429-436
46. Schatzberg A.F. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry 68 Suppl 8 (2007) 26-34
47. Schur S.B., Sikich L., Findling R.L., Malone R.P., Crismon M.L., Derivan A., et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatry 42 2 (2003) 132-144
48. Selim K., and Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology 29 (1999) 1347-1351
49. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 (2004) e634-e641
50. Sherlock S., and Dooley J. Diseases of the liver and biliary system. 9th ed. (1993), Blackwell Scientific Publications, Oxford, England, and Boston
51. Sikich L., Hamer R.M., Bashford R.A., Sheitman B.B., and Lieberman J.A. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29 (2004) 133-145
52. Simeon J., Milin R., and Walker S. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 26 2 (2002) 267-275
53. Snyder R., Turgay A., Aman M., Binder C., Fisman S., and Carroll A. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41 (2002) 1026-1036
54. Steiner H. Practice parameters for the assessment and treatment of children and adolescents with conduct disorders. J Am Acad Child Adolesc Psychiatry 36 suppl 10 (1997) 122-139
55. Szigethy E., Wiznitzer M., Branicky L.A., Maxwell K., and Findling R.L. Risperidoneinduced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 9 2 (1999) 93-98
56. Thomas L. Enzymdiagnostik. In: Thomas L. (Ed). Labor und Diagnose (1995), Medizinische Verlags-Gesellschaft, Marburg 39-160
57. Turgay A., Binder C., Snyder R., and Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110 (2002) e34
58. Whitworth A.B., Liensberger D., and Fleischhacker W.W. Transient increase of liver enzymes induced by risperidone: two case reports. J Clin Psychopharmacol 19 5 (1999) 475-476
59. Wigal S., Abikoff H., Kollins S., McCracken J., Riddle M., Posner K., et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 45 11 (2006) 1294-1303
60. Zuddas A., Di Martino A., Muglia P., and Cianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10 2 (2000) 79-90